Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Ipilimumab in Advanced RCC (India)
NCT04513522Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2020
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of nivolumab, ipilimumab in renal cell carcinoma (RCC), sponsored by Bristol Myers Squibb. Started Dec 2020; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04513522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04513522.